article thumbnail

Social Determinants of Health Shape Pain Outcomes in Sickle Cell Disease

HCPLive

Education and employment, social and emotional functioning, and healthcare access are notable factors influencing pain in sickle cell disease.

article thumbnail

Presence of CKD in Sickle Cell Disease Worsens In-Hospital Outcomes

HCPLive

Chronic kidney disease was linked to increased mortality, higher costs, and the need for mechanical ventilation among hospitalized patients with sickle cell disease.

article thumbnail

Hematology Month in Review: March 2024

HCPLive

Our March 2024 month-in-review in hematology features updates to the anemia pipeline, the latest research in sickle cell disease, and the role of SGLT2 inhibition on hematologic outcomes.

article thumbnail

Universal Newborn Screening Pivotal for Sickle Cell Disease Outcomes

HCPLive

Early detection from a universal newborn screening program in Canada significantly reduced disease-related burden in children with SCD.

article thumbnail

Hematopoietic Stem Cell Transplantation Improves Pediatric SCD Outcomes

HCPLive

A systematic review and meta-analysis of HSCT in children with sickle cell disease demonstrated pooled survival rates exceeding 90%.

article thumbnail

Dexamethasone Raises VTE Risk in COVID-19 Cases with Sickle Cell

HCPLive

Dexamethasone treatment was linked to worse clinical outcomes in patients with sickle cell disease hospitalized for COVID-19.

article thumbnail

Lantheus Announces the FDA Approval of DEFINITY as Ultrasound Enhancing Agent for Use in Certain Pediatric Cardiovascular Patients

DAIC

Patients with sickle cell disease may be at higher risk of painful crisis and DEFINITY® should be administered with caution. Clinical studies have substantiated the efficacy and safety of DEFINITY in pediatric patients, reported the company, which is Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden.